Search jobs 10-Mar-2021 SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting
WATERTOWN, Mass. (BUSINESS WIRE) SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next generation SQZ™ APCs and the broader applicability of the APC platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting being held virtually April 10-15, 2021. SQZ APC is a cell therapy platform that aims to induce powerful antigen specific CD8+ T cell responses. Two posters will highlight the additional functionality of enhanced APCs (eAPCs) and potential patient population expansion by leveraging multiple mRNA based cargos. A third poster describes SQZ APCs in development for additional tumor types target